Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system

Nuclear Medicine Communications

Volumn 32, Issue 10, 2011, Pages 887-895

  Petrik, Milos ^a   Knetsch, Peter A ^a   Knopp, Roger ^c   Imperato, Giovanni ^c   Ocak, Meltem ^a,d   Von Guggenberg, Elisabeth ^a   Haubner, Roland ^a   Silbernagl, Roland ^b   Decristoforo, Clemens ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c Eckert and Ziegler Eurotope GmbH   (Germany)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

automation; diagnostics and therapy; radiolabelled peptides; radiopharmaceuticals

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NAL3 OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYR3 OCTREOTATE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYR3 OCTREOTATE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYR3 OCTREOTATE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYR3 OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYR3 OCTREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYR3 OCTREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC TYR3 OCTREOTATE ACID LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; AUTOMATION; CONTROLLED STUDY; DRUG PURIFICATION; DRUG PURITY; DRUG SYNTHESIS; FILTRATION; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIATION SAFETY; RADIATION SHIELD; REVERSED PHASE LIQUID CHROMATOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYRINGE; THIN LAYER CHROMATOGRAPHY;

AUTOMATION; DISPOSABLE EQUIPMENT; EQUIPMENT SAFETY; HETEROCYCLIC COMPOUNDS, 1-RING; ISOTOPE LABELING; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; ROBOTICS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 80052476741     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283497188     Document Type: Article

References (29)

1. Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005; 12:683-699. (Pubitemid 41815771)
2. 68Ga-labeled peptides in tumor imaging. J Nucl Med 2005; 46:172-178.
3. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006; 36:228-247. (Pubitemid 43817847)
4. Van Essen M, Krenning EP, De Jong M,Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007; 46:723-734. (Pubitemid 47123757)
5. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009; 50:1427-1434.
6. De Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res 2009; 42:873-880.
7. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004; 31:1097-1104. (Pubitemid 39050176)
8. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003; 30:917-920. (Pubitemid 36734213)
9. Virgolini IJ, Gabriel M, Von Guggenberg E, Putzer D, Kendler D, Decristoforo C. Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours. Eur J Cancer 2009; 45:274-291.
10. Decristoforo C, Penuelas I. Towards a harmonized radiopharmaceutical regulatory framework in Europe? Q J Nucl Med Mol Imaging 2009; 53:394-401.
11. Elsinga P, Todde S, Penuelas I, Meyer G, Farstad B, Faivre-Chauvet A, et al. Radiopharmacy Committee of the EANM. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2010; 37:1049-1062.
12. Ellison D, Kaufman J, Mather SJ. Automated radiolabelling of monoclonal antibodies with the Modular Lab system. Nucl Med Commun 2010; 31:173-177.
13. 68Ga- labelled peptides. Nucl Med Commun 2007; 28:870-875. (Pubitemid 47494113)
14. 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2008; 35:1507-1515.
15. 68Ga labelling of DOTA-peptides including cation exchange prepurification. Appl Radiat Isot 2010; 68:297-302.
16. 68Ga for medical application. J Nucl Med 2007; 48:1741-1748. (Pubitemid 47572722)
17. 68Ga-peptide preparation using processed generator eluate. J Nucl Med 2010; 51:495.
18. 18F-fluorine. J Nucl Med 2010; 51:454-461.
19. 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjugate Chem 2008; 19:569-573. (Pubitemid 351294931)
20. Haubner R, Beer AJ, Wang H, Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging 2010; 37:86-103.
21. Dijkgraaf I, Boerman OC. Molecular imaging of angiogenesis with SPECT. Eur J Nucl Med Mol Imaging 2010; 37:104-113.
22. Janssen M, Frielink C, Dijkgraaf I, Oyen W, Edwards DS, Liu S, et al. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother Radiopharm 2004; 19: 399-404. (Pubitemid 39281331)
23. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 2007; 48:615-622. (Pubitemid 47571419)
24. Good S, Walter MA, Waser B, Wang X, Müller-Brand J, Béhé MP, et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging 2008; 35:1868-1877.
25. 111In-labelled minigastrin. Eur J Nucl Med Mol Imaging 2008; 35:386-392.
26. Helbok A, Decristoforo C, Behe M, Rangger C, Von Guggenberg E. Preclinical evaluation of In-111 and Ga-68 labelled minigastrin analogs for CCK2 receptor imaging. Curr Radiopharm 2009; 2: 304-310.
27. 68Ga-siderophores for PET imaging of invasive pulmonary aspergillosis: proof of principle. J Nucl Med 2010; 51:639-645.
28. Pascali G, Mazzone G, Saccomanni G, Manera C, Salvadori PA. Microfluidic approach for fast labeling optimization and dose-on-demand implementation. Nucl Med Biol 2010; 37:547-555.
29. 90Y-ibritumomab tiuxetan (HD-Zevalin). Nucl Med Biol 2010; 37: 85-93.